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PLATELETS AND THROMBOPOIESIS
A GWAS sequence variant for platelet volume marks an alternative DNM3
promoter in megakaryocytes near a MEIS1 binding site
*Sylvia T. Nu¨rnberg,1 *Augusto Rendon,1,2 Peter A. Smethurst,1 Dirk S. Paul,3 Katrin Voss,1 Jonathan N. Thon,4,5
Heather Lloyd-Jones,1 Jennifer G. Sambrook,1 Marloes R. Tijssen,1,6 the HaemGen Consortium, Joseph E. Italiano Jr,4,7
Panos Deloukas,3 Berthold Gottgens,6 Nicole Soranzo,3 and Willem H. Ouwehand1,3
1Department of Haematology, University of Cambridge and National Health Service Blood and Transplant, Cambridge, United Kingdom; 2Biostatistics Unit,
Medical Research Council, Cambridge, United Kingdom; 3Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom;
4Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA; 5Harvard Medical School, Boston, MA; 6Department of
Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; and 7Vascular Biology Program, Department of
Surgery, Children’s Hospital, Boston, MA
We recently identified 68 genomic loci
where common sequence variants are
associated with platelet count and vol-
ume. Platelets are formed in the bone
marrow by megakaryocytes, which are
derived from hematopoietic stem cells by
a process mainly controlled by transcrip-
tion factors. The homeobox transcription
factor MEIS1 is uniquely transcribed in
megakaryocytes and not in the other
lineage-committed blood cells. By ChIP-
seq, we show that 5 of the 68 loci pinpoint
a MEIS1 binding event within a group of
252 MK-overexpressed genes. In one such
locus in DNM3, regulating platelet vol-
ume, the MEIS1 binding site falls within a
region acting as an alternative promoter
that is solely used in megakaryocytes,
where allelic variation dictates different
levels of a shorter transcript. The impor-
tance of dynamin activity to the latter
stages of thrombopoiesis was confirmed
by the observation that the inhibitor Dyna-
sore reduced murine proplatelet for-
mation in vitro. (Blood. 2012;120(24):
4859-4868)
Introduction
A genome-wide association meta-analysis study (GWAS) in nearly
67 000 persons identified 68 independent loci associated with the
mean platelet volume (MPV) and the count of platelets (PLT) at
genome-wide (GW) significance, representing an ideal resource to
make discoveries in megakaryocyte (MK) and PLT biology.1
Although such GWASs unequivocally identified loci that are
implicated in the formation and survival of PLTs, to confirm which
genetic variants are responsible for the observed associations and
which genes mediate their effects remains a challenge. Strategies to
prioritize functional follow-up studies are therefore highly desired.
Fifteen of the 68 loci are likely to act through nonsynonymous
variants. The remaining 53 loci have potential roles in altering
transcriptional regulation. Indeed, at one of the MPV loci at
chromosome 7q22.3, we recently showed that the minor allele of
the noncoding variant rs342293 disrupts a binding site of the
transcription factor EVI1/MECOM, leading to a higher transcript
level of the downstream gene PIK3CG.2
Here we present a strategy to prioritize the functional follow-up
of GWAS hits whereby sentinel single nucleotide polymorphisms
(SNPs; those with the lowest P value at an associated locus) and
those in strong linkage disequilibrium (r2  0.8 in Europeans;
proxy SNPs hereafter) are overlapped with the GW DNA binding
patterns of a lineage restricted transcription factor as deter-
mined experimentally by ChIP combined with deep sequencing
(ChIP-seq). This strategy has the advantage of providing
hypotheses about the underlying genetic mechanisms behind the
observed associations that can be readily followed. We selected
the transcription factor MEIS1 for several reasons. First, this
3 amino acid loop extension homeodomain protein was identi-
fied as a common viral integration site in myeloid leukemias of
BXH-2 mice3 and has since been established as a strong
regulator of hematopoiesis and myeloid leukemogenesis.4-7
Second, MEIS1 is exclusively transcribed in hematopoietic
stem/progenitor cells and in the MK lineage; therefore, MEIS1
binding events are highly likely to be critical for the identity of
this lineage.8,9 Third, gene knockout in mice results in early
embryonic lethality with a complete lack of megakaryopoi-
esis,10,11 and knockdown studies of meis1 in zebrafish showed
major effects on both hematopoiesis and vasculogenesis, confirm-
ing the abrogation of the formation of thrombocytes, the fish
equivalent of MKs and PLTs.12,13 Finally, little is known about
how MEIS1 regulates megakaryopoiesis, resulting in these
striking phenotypes.
In this study, we report on the successful identification of a set
of MEIS1-regulated genes by ChIP-seq in megakaryocytic cells.
The set is significantly enriched for genes implicated in megakaryo-
poiesis and PLT function and contains, as postulated, more PLT
GWAS loci than to be expected by chance. Detailed functional
studies of a dynamin isoform DNM3, one of the identified GWAS
loci that colocalizes with a binding event, revealed that MEIS1
binds a novel promoter that is uniquely used in the megakaryocytic
lineage and where the promoter activity displays differential allelic
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effects at the putative functional variant. We show that the
formation of pro-PLTs from murine in vitro–derived MK was
inhibited by the dynamin inhibitor Dynasore, confirming the
importance of dynamin activity to the late stages of
megakaryopoiesis.
Methods
Cell culture
CHRF 288-11 cells14 (hereafter CHRF cells) were cultured in RPMI 1640
(Sigma-Aldrich), 10% FBS (Invitrogen), and 200M L-glutamine,
100 U penicillin, and 100 g/mL streptomycin (Sigma-Aldrich). The
1603MED cells15 were cultured in DMEM, high glucose, with sodium
pyruvate, without L-glutamine (PAA Laboratories), and supplemented with
10% FBS, 1% nonessential amino acids (HyClone, Thermo Scientific), and
200M L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin.
MK culture
MKs were obtained by culture of CD34 hematopoietic progenitor cells as
previously reported.16 In short, cord blood was collected with informed
consent, and CD34 cells were prepared by magnetic bead selection.
Purified cells were cultured (1  105 cells/mL) for up to 12 days in
serum-free medium supplemented with human thrombopoietin and IL-1
to differentiate into MKs. Cells were also harvested at days 3, 5, 7, 9, 10,
and 12 and characterized by immunophenotyping with monoclonal antibod-
ies against relevant CD markers and by analysis of RNA on Illumina whole
genome expression arrays.1 By day 10,  90% of cells stained positive for
CD41 and negative for CD34.
ChIP and massive parallel sequencing
Twenty million CHRF cells per condition were crosslinked for 10 minutes
with 1% formaldehyde. Cells were lysed for 10 minutes on ice (10mM Tris,
pH 8.0, 10mM NaCl, 0.2% NP-40). Nuclei were then lysed for 10 minutes
on ice (50mM Tris, pH 8.1, 10mM EDTA, 1% SDS). Crosslinked chromatin
was sheared for 2  5 minutes by sonication using a Bioruptor (Diagenode)
and precleared with 100 g anti–rabbit IgG preimmune serum (Sigma-
Aldrich) using protein G-Sepharose beads (Roche Diagnostics). ChIP was
performed overnight in IP dilution buffer (20mM Tris, pH 8.1, 2mM EDTA,
150mM NaCl, 1% Triton X-100, 0.01% SDS), using 14 g anti-MEIS1
(Abcam, ab19867, lot no. 153899) or anti–rabbit IgG (Sigma-Aldrich
I5006, lot no. 115K7551), respectively. Beads were washed twice with
buffer 1 (20mM Tris, pH 8.1, 2mM EDTA, 50mM NaCl, 1% Triton X100,
0.1% SDS), once with buffer 2 (10mM Tris, pH 8.1, 1mM EDTA, 250mM
LiCl, 1% NP40, 1% sodium deoxycholate monohydrate), and twice with TE
(10mM Tris, 1mM EDTA, pH 8.0) buffer. Bound chromatin was eluted
from the beads twice with 100mM NaHCO3 containing 1% SDS. After
reverse crosslinking and RNaseA and proteinase K digestion, chromatin
was cleaned up using the QIAGEN PCR purification kit (QIAGEN).
ChIP-seq library generation, cluster formation, and sequencing were
performed at the Michael Smith Genome Sciences Center (Vancouver, BC)
on an Illumina GAII analyzer. The resulting 9 513 449 single-end reads
were mapped to the human genome (hg19) using stampy 1.0.11_(r880).17
Of the reads, 7 323 093 were of high mapping quality ( 30). Peaks were
called using MACS18 and PICS.19 Peak overlap was generated by requiring
a minimum overlap of 150 nucleotides. Results were deposited at ArrayEx-
press (www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-859.
Overlap with GWAS loci and significance analysis
For each of the 68 associated loci, candidate functional SNPs were selected
by identifying all single nucleotide variants with an r2  0.8 and within
100 kb of the sentinel SNP in the European samples of the 1000 Genomes
project (June 2011 release). To establish whether the association of a locus
could potentially be of regulatory origin, we determined whether at least
one candidate functional SNP overlapped with a ChIP-seq peak. Because
the chance of identifying an overlap between a sentinel SNP and a MEIS1
binding peak is sensitive to the number of peaks considered, the over-
lap analysis was carried by successively increasing the number of peaks
by including peaks with decreasing peak height. We estimated the
significance of observing a given number of overlaps by resampling. A total
of 50 000 sets of 66 loci (2 GWAS SNPs in the HLA locus were removed
because of its complicated haplotype structure) were drawn from the same
SNPs onto which the GWAS data were imputed ( 2.5 million SNPs from
HapMap2)20 while preserving the distribution of allele frequencies. All
analyses were carried out in the R/Bioconductor environment.
Functional analysis of MEIS1 binding sites
To identify annotated protein coding genes enriched in the proximity of
MEIS1 binding sites, the set of 13 842 peaks jointly called by 2 algorithms
was analyzed using the GREAT software (Version 1.8.1).21 Enrichment was
tested against the whole human genome (hg19) using standard parameters.
Significance was measured by binomial P values and the false discovery
rate q values. In addition, a set of 1285 protein coding genes with MEIS1
binding sites located within an annotated gene body, including 5 kb each
upstream and downstream, was tested for over-representation of Gene
Ontology terms using FatiGO as part of the Babelomics Version 4.2
environment.22 Enrichment was tested compared with the rest of the human
genome. Adjusted P values stem from the Fisher exact test, after correcting
for multiple testing, using the false discovery rate procedure of Benjamini
and Hochberg.23
RNA sequencing
Total RNA from 10 day cultured MKs was obtained by the Trizol method as
described.16 Polyadenylated RNA was purified from this by 2 rounds of
magnetic Oligo dT25 selection (Dynabeads Oligo (dT)25, Invitrogen) in the
presence of RNase inhibitor (New England Biolabs), combined with DNase
treatment (Ambion, Invitrogen). The mRNA was fragmented using RNA
fragmentation reagent (Ambion, Invitrogen) and precipitated with added
glycogen (Ambion), then cDNA produced by Superscript Double Stranded
cDNA synthesis kit (Invitrogen), replacing oligo-dT primer with random
primer. Thereafter, library preparation was as per mRNA-sequencing kit
(Illumina), starting with end repair. Bands of  300-450 bp were gel
extracted for paired-end sequencing by Illumina GAII analyzer with a read
length of 76 bp. The RNA-seq results are deposited at ArrayExpress under
accession number E-MTAB-918.
FAIRE
Formaldehyde-assisted isolation of regulatory elements (FAIRE) experi-
ments were carried out as previously described.24 In short, 20 million cells
were cross-linked with 1% formaldehyde for 12 minutes and subjected to
12 sonication cycles using the Bioruptor UCD-200. The sample was
cleaned-up using the MinElute PCR Purification Kit (QIAGEN). FAIRE
DNA was processed following the Illumina paired-end library generation
protocol. The genomic libraries were sequenced at 54-bp paired-end reads
on an Illumina GAII analyzer. Sequence reads were aligned to the human
genome (hg19) using stampy 1.0.11_(r880) with default parameters. The
FAIRE-seq data are deposited at ArrayExpress under accession number
E-MTAB-858.
MPV
EDTA anticoagulated blood from volunteers of the Cambridge BioResource
(http://www.cambridgebioresource.org.uk) was obtained with informed
consent under the Cardiosome Project: Genes and Mechanisms in Cardio-
vascular Disease. Ethical approval for this study, conducted in accordance
with the Declaration of Helsinki, was given by the Cambridgeshire
1 Research Ethics Committee. Full blood counts, including the measure-
ment of MPVs, were obtained from blood samples within 2 hours after
collection using a Coulter LH500 hematology analyzer (Beckman-Coulter).
Platelet isolation
Citrate anticoagulated samples of blood were obtained from Cambridge
BioResource volunteers and centrifuged for 20 minutes at 150g to obtain
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PLT-rich plasma (PRP). The PRP was centrifuged twice more, each time
retaining the supernatant and discarding the leukocyte-rich pellet together
with the 0.5-mL PRP layer immediately above it. The PRP was further
leukocyte-depleted by mixing with anti-CD45 magnetic beads (Dynabeads
CD45, Invitrogen; 33 L beads/mL of PRP) and rotating at room tempera-
ture for 20 minutes. The beads were removed by Dynal MPC-L magnet,
using 2 cycles of 2-minute magnetization steps and transferring the PRP to
fresh tubes after each step. The leukocyte-depleted PRP was centrifuged for
10 minutes at 1500g. The supernatant was discarded and the PLT pellet
resuspended in 2 mL Trizol (Invitrogen) until a particle-free solution was
obtained; 1-mL aliquots were frozen on dry ice and stored at 80°C.
Starting PRP volumes ranged from 5 to 15 mL, and corresponding yields
ranged from 0.5 to 2.5  109 PLTs.
RNA preparation and cDNA synthesis
RNA from cultured cells and PLTs was prepared using Trizol essentially
according to the manufacturer’s instructions, except that 2-mL Phase
Lock Gel tubes (5) were used for the phase separation. RNA pellets
were air dried for no more than 7 minutes and then resuspended in 15 L
nuclease-free water (Ambion, Invitrogen). RNA yields averaged 940 ng/
109 PLTs with A260/280 ratios between 1.33 and 1.66. The 25-ng PLT
RNA was processed by the ABI TaqMan Reverse Transcription Reagents
(Applied Biosystems) in a 25-L volume, according to the manufactur-
er’s protocol. At the end of the reaction, RNA was diluted to 250 L
with nuclease-free water and stored at 20°C. In addition, total RNA
from human brain (P/N #54005, 54007, and 540117) was obtained from
Stratagene (Agilent Technologies).
Gene expression quantitative real-time PCR
Absolute quantification of DNM3 transcript abundance in RNA samples
from human PLTs and other cells was carried out on a ABI Prism 7900HT
Sequence Detection System (Applied Biosystems) using the following
protocol: 50°C 2 minutes, 95°C 10 minutes, 40  (95°C 15 seconds,
60°C 1 minute). Product numbers of the used TaqMan gene expression
assays (Applied Biosystems) can be found in supplemental Table 1
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article). To test for abundance of the novel DNM3
transcript variant, a custom TaqMan assay was designed with the probe
spanning the boundary between the novel exon 2B and exon 3. Transcript
levels were normalized to GAPDH. Reactions were measured in triplicate
and primer efficiencies obtained through cDNA standard dilution series.
RACE
5-Rapid amplification of cDNA ends (RACE) on RNA samples from
CHRF and MK cells and PLTs was performed using the 5/3 RACE Kit,
2nd Generation (Roche Diagnostics) following the manufacturer’s proto-
col. For the PCR amplification steps, recombinant Taq polymerase and
dNTPs from Fermentas were used (Fermentas). DNA fragments were
subcloned into pGem T easy (Promega) and sequenced. Primer and clone
sequences can be found in supplemental Table 2.
Dual Luciferase reporter assays
DNA fragments were cloned into the firefly Luciferase vector pGl4.10
(Promega). Ten million cells were transfected with 10 g firefly Luciferase
vector and 500 ng Renilla Luciferase vector pGl4.74 (Promega). Transfec-
tion was performed via electroporation using a Bio-Rad GenePulser Xcell
(exponential curve, 220 V, 900 F, resistance 	, 4-mm cuvettes). Lu-
ciferase activity was measured in a LUMIstar Optima luminometer (BMG
Labtech) using the Dual-Luciferase Reporter Assay kit (Promega). Random
DNA sequences for use as negative controls were generated by the Random
DNA Sequence Generator (http://www.faculty.ucr.edu/mmaduro/random.
htm) and produced by artificial gene synthesis (GeneArt). For sequences of
cloning primers and construct inserts, see supplemental Table 3.
Electrophoretic mobility shift assay
See supplemental Methods.
MK suspension cultures
Mouse fetal liver cells were collected from WT CD1 mice (Charles River
Laboratories) on day E13.5 and cultured at 37°C and 5% CO2 in the
presence of 0.1 g/mL purified recombinant mouse c-Mpl ligand for
5 days. Fetal liver cell cultures were layered on a single-step gradient
(1.5%-3.0% BSA) on culture day 4, and MKs were allowed to sediment for
30 minutes
.
25 The MK pellet was then resuspended in fresh media and
cultured for an additional 24 hours alone or in the presence of either
0.3% DMSO or 100M DynaSore in DMSO. MK cultures were examined
on day 5 by phase-contrast microscopy using a Nikon eclipse TS100
benchtop microscope (Nikon) at 20 magnification; digital images were
collected on a Hamamatsu C2400 CCD camera and analyzed using ImageJ.
Mature MKs were identified by size ( 10m diameter) and distinguished
from pro-PLT-producing MKs because of the presence or absence of long
pro-PLT elongations (circularity  0.7). Samples were examined in tripli-
cate, and at least 78 cells were counted for each condition tested. All studies
complied with institutional guidelines approved by the Children’s Hospital
animal care and use committee, and the Institutional Animal Care and Use
Committee.
Statistical analysis
Results are expressed as mean 
 SD with number of experiments.
Statistical comparisons between groups were performed by 2-tailed t test
using Prism unless stated otherwise. Statistical comparisons of Luciferase
data were performed on log transformed signal intensities using mixed
linear models to account for the hierarchical nature of the data.
Results
MEIS1 putatively regulated genes are important determinants
of the PLT lineage
The expression of MEIS1 is restricted to the megakaryocytic
lineage, among differentiated blood cells (supplemental Figure
1).8,9 To map MEIS1 binding events, we performed ChIP-seq in the
human megakaryocytic cell line CHRF, a close model for MKs
based on its transcriptional profile (supplemental Figure 2). MEIS1
peaks were called using magnetic-activated cell sorting18 and
PICS19 from which a high-confidence dataset of 13 842 binding
events detected by both algorithms was generated (Figure 1A).
Genes nearby MEIS1 binding events were analyzed with GREAT21
(Genomic Regions Enrichment of Annotations Tool), revealing that
putatively regulated genes are significantly over-represented in
megakaryopoiesis and PLT biology categories (Table 1; supplemen-
tal Figure 3). To increase stringency in assigning putatively
regulated genes, a list of 1285 potentially MEIS1-regulated genes
was generated by filtering for peaks with a minimum height of
30 reads (80th percentile of peak height) and within 
 5 kb of
protein coding genes (supplemental Methods). Analysis of their
expression patterns showed a significant over-representation of 57
genes of a set of 252 that were shown to be strongly overexpressed
in MKs relative to the other 7 mature blood cell types
(P  5  1019; Figure 1B) in the HaemAtlas compendium of
blood cell transcripts.8 These observations are consistent with our
hypothesis that MEIS1, because of its characteristic lineage restric-
tion, regulates many genes critical to the identity of MKs and PLTs.
Indeed, these 57 genes contain many well-known regulators of
their function, such as the collagen signaling receptor GlycoProtein
(GP) VI (GP6), 1 of the 4 subunits of the PLT receptor for von
Willebrand Factor, GPV (GP5), and the  granule membrane
protein P-selectin (SELP).
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MEIS1 binding profile aids in the prioritization of functional
studies of GWAS loci
Six of the 57 MK overexpressed genes with a MEIS1 binding site
(Figure 1B genes labeled in bold) harbored a sentinel GWAS SNP.
Importantly, a GW analysis of the spatial co-occurrence of MEIS1
binding peaks with 66 sentinel SNPs (2 GWAS SNPs in the HLA
locus were removed because of its complicated haplotype
structure) for PLT volume and count and their proxy SNPs
robustly identified at least 5 sites of colocalization when only
the top 20% of MEIS1 peaks was considered (Figure 2A). Such
degree of overlap was significantly greater than expected by
chance (P  1  105).
To investigate the consequences of the observed colocalization,
we selected the DNM3 locus because the locus is strongly
associated with MPV (sentinel SNP rs10914144 P 1.11 1024),
and there are no other genes localized in the recombination interval
that harbors this variant. The sentinel SNP (minor allele frequency
in Europeans 0.173; 2.99% of persons are homozygous for the
minor allele) is noncoding, and no coding proxy SNPs could be
identified in the 1000 Genomes project catalog.26 Moreover,
whereas DNM2 is ubiquitously expressed, DNM1 and DNM3 show
tissue-specific expression profiles,27,28 whereby in hematopoiesis,
DNM3 expression is restricted to the megakaryocytic lineage
(Figure 2B; supplemental Figure 4). In other tissues, DNM3
transcript is also found in brain, lung, heart, and testis (supplemen-
tal Figure 5A-B).8,9,29,30
MEIS1 and variant rs2038479 co-occur in the proximity of a MK
specific alternative DNM3 transcription start site
In the DNM3 gene locus, the MEIS1 binding event occurs very
close to, although does not contain, variant rs2038479 (90 bp from
MEIS1 peak maximum). This variant is 10 460 bp upstream and in
strong linkage disequilibrium with the GWAS sentinel SNP
rs10914144 (r2  0.991 in Europeans; 1000 Genomes, June 2011
release). Both the MEIS1 binding site and variant rs2038479 lie at a
Figure 1. MEIS1 ChIP-seq identifies genes regulating
MK and PLT biology. (A) MEIS1 ChIP-seq in CHRF
288-11 cells identifies mainly intronic and intergenic
binding sites. (B) Cellular functions of 57 genes with
MEIS1 binding events and overexpressed in MKs. Bold
represents 6 loci containing sentinel SNPs associated
with MPV or PLT count.
Table 1. Functional assessment of MEIS1 binding sites by GREAT
shows enrichment of megakaryocyte and platelet phenotypes
Enriched term Noncorrected P FDR adjusted q
Mouse phenotype
Abnormal platelet physiology 6.5  1030 7.3  1028
Abnormal platelet activation 4.3  1022 3.3  1020
Abnormal platelet aggregation 1.1  1021 7.8  1020
Decreased platelet aggregation 6.6  1020 4.1  1018
Abnormal vascular branching
morphogenesis
1.0  1019 6.0  1018
Increased bleeding time 7.3  1019 4.0  1017
Decreased common myeloid
progenitor cell number
3.9  1014 1.4  1012
Abnormal bone marrow development 6.4  108 1.2  106
MSigDB pathway
Pertussis toxin-insensitive CCR5
signaling in macrophage
4.6  1013 5.1  1011
TPO signaling pathway 1.5  109 4.5  108
MSigDB perturbation
Genes essential to the development of
megakaryocytes, as expressed in
normal cells and essential
thrombocythemic cells
1.7  1022 2.4  1020
FDR indicates false discovery rate; MSigDB, molecular signatures database; and
TPO, thrombopoietin (the principal growth factor for megakaryocytes).
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putative promoter of an alternative transcript ENST00000523513
(termed alternative transcript hereafter) that is so far solely
based on EST clones derived from CD34 cells obtained from
cord blood (AF150278 and AV739470). RNA-seq data for
cultured MK revealed transcription surrounding rs2038479
(Figure 3B), suggesting a novel DNM3 exon of  133 bp (exon
2B hereafter). 5 RACE with RNA from cultured MKs, CHRF
cells, and PLTs (Figure 3C) confirmed the expression of exon 2B
and the presence of an alternative transcription start site.
Furthermore, RACE analysis revealed that exons 1 and 2 are not
part of the predominant DNM3 transcript in MKs (see supplemen-
tal Table 2 for RACE clone sequences). Using primers in exon
2B and the annotated 3-untranslated region, a PCR product was
obtained from MK cDNA that contained an open reading frame
extending from exon 2B to the annotated stop codon after
Asp859 (data not shown).
Because the annotated DNM3 consensus transcript is derived
from human brain tissue, we quantified expression levels of both
transcripts in cerebellum and MKs. This revealed a striking
tissue specific expression pattern, with the consensus transcript
being used in the former and the alternative one in the latter
(Figure 4B). Indeed, expression of the alternative transcript
appears restricted to the megakaryocytic lineage (supplemental
Figures 5 and 6A-C), with the expression of this isoform
substantially increasing during megakaryopoiesis (Figure 4C;
supplemental Figure 6D).
Variant rs2038479 displays allelic differences in the promoter
activity of the MK specific DNM3 transcript
To test whether the variant affected DNM3 expression, we typed
the sentinel SNP rs10914144 in 5034 healthy volunteers from the
Cambridge BioResource and recalled 2 groups of 26 persons
homozygous for each allele. Typing of the samples for rs2038479
showed complete concordance in all but 1 sample from a person
homozygous for the minor allele of rs10914144, which tested
heterozygous for rs2038479. MPV and PLT DNM3 RNA levels
were compared between groups and, as expected, the minor allele
was associated with lower MPV, consistent with the GWAS results
derived from nearly 67 000 persons (P .03; Figure 2C). Compari-
son of the PLT DNM3 transcript levels with a probe specific for
the alternative exon 2B revealed a statistically significant differ-
ence between groups, with lower levels in persons homozygous for
the minor allele (P  .0036; Figure 4A). This difference was not
observed with a probe specific for the consensus transcript
(P  .9967).
Luciferase reporter constructs for the consensus and alternative
promoters confirmed the quantitative PCR data. Whereas the
consensus promoter was active in both CHRF and 1603MED (a
human medulloblastoma cell line) cells, the alternative one was
exclusively active in CHRF cells (Figure 4D). We then tested the
effect of the rs2038479 variant on the activity of the alternative
promoter and observed reduced activity in CHRF cells with the
minor versus the major allele (Figure 4D; P  .002), which is
Figure 2. DNM3 harbors MEIS1 binding sites and is
associated with differences in MPV. (A) Co-occurrence
of MPV and PLT count association SNPs with MEIS1
ChIP-seq peaks. (B) Transcript levels of DNM genes
during in vitro differentiation of MKs from human cord
blood CD34 cells, as measured by quantitative real-
time RT-PCR (n  3). Error bars represent SD. (C) MPV
of the PLTs of persons according to genotype for sentinel
SNP rs10914144 (n  26 of 26). Mann-Whitney test:
P  .03.
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consistent with the allelic differences in PLT DNM3 transcript
levels between the 2 genotype groups. Electrophoretic mobility
shift assay with probes harboring alternative forms of rs2038479
incubated with CHRF nuclear lysates displayed a striking differ-
ence between the 2 alleles with strong band shifting for the minor
allele, thus revealing preferential binding of nuclear factors to this
allele (supplemental Figure 7). Taken together, these data strongly
suggest that rs2038479 is the more likely causative variant
underlying the observed association with MPV, resulting in in-
creased binding of a repressor complex at this locus.
Loss of Dynamin activity results in impaired pro-PLT formation
We reasoned, because of the observed positive correlation between
PLT DNM3 transcript levels and MPV (Figures 2C and 4A), that
inhibition of the DNM proteins may exert an effect on the processes
of megakaryopoiesis and pro-PLT formation. To test this, MKs
were generated by culture of murine fetal liver cells in the presence
and absence of Dynasore, an inhibitor of DNM GTPase activity.31
The proportion of MKs that formed pro-PLT processes was
recorded (Figure 5A) and compared between the treated and
control cultures. A significant reduction was observed (Figure 5B),
providing additional evidence for the importance of DNM activity
in this process.
Discussion
The volume and count of PLTs vary widely in the healthy
population but are tightly regulated within narrow ranges at the
individual level. The population variation in MPV and PLT is for a
large extent genetically controlled. In a GWAS in nearly 67 000
persons of European ancestry, we identified 68 independent genetic
loci associated with either or both PLT traits at GW significance.1
The sentinel SNP of 54 of the loci mapped within 10 kb of a gene
providing probable biologic candidate proteins. At 15 of the
54 loci, the sentinel SNP or a proxy SNP in high linkage
disequilibrium (r2  0.8) altered the amino acid sequence of the
implicated protein, thus providing a plausible functional explana-
tion for the observed associations. The sentinel SNPs at the
53 remaining loci are synonymous or noncoding ones, generally
localized in introns or sometimes in intergenic regions and
therefore are likely to exert their effect on megakaryopoiesis and
the formation and survival of PLTs by regulating gene transcrip-
tion, possibly through lineage-specific regulatory elements.2
Here we have presented a prioritization strategy to select genes
and variants for functional follow-up studies to investigate their
role in the megakaryocytic lineage based on only considering
associated variants that are also located at MEIS1 binding sites.
This has resulted in a small list of readily tractable loci of which we
selected DNM3 for in-depth analysis.
A similar overlapping strategy has been adopted previously
using regions of open chromatin as markers for regulatory elements
as determined by FAIRE. For example, in Paul et al,2 we used
FAIRE-ChIP to identify potential regulatory variants and showed
that the major (C) allele of the MPV variant rs342293 at 7q22.3 is
bound by the transcription factor EVI1/MECOM more firmly than
the minor (G) allele. Binding of EVI1/MECOM to the major allele
at this position is likely to be associated with repression of
transcription and results in a lower PIK3CG transcript level in
persons homozygous for the major allele compared with those
homozygous for the minor allele. Although the selection of
EVI1/MECOM as likely candidate was based on computational
prediction followed by experimental validation, the present study
used in vivo transcription factor binding to prioritize potential
regulatory variants.
To explore the mechanisms that underlie the observed
associations between noncoding sequence variants and the PLT
traits of volume and count, we chose to focus on the transcrip-
tion factor MEIS1. In lineage-committed blood cells MEIS1 is
uniquely transcribed in megakaryocytic cells, and not in the
other 7 major mature blood cell types (supplemental Figure 1).8
The functional role of MEIS1 in hematopoiesis and leukemogen-
esis has been studied extensively,32-34 but its role in megakaryo-
poiesis and PLT formation has not yet been fully appreciated. In
this study, we postulated that a fraction of the association SNPs
identified by GWAS or their proxy SNPs may modify target
Figure 3. The DNM3 locus harbors a regulatory element and an alternative exon
in annotated intron 2. (A) DNM3 gene locus showing CEU LOD plot (HapMap
release 22). (B) Close-up of gene region, including exons 1-4 with regional plots from
FAIRE-seq, MEIS1 ChIP-seq, and RNA-seq data. Also depicted are key SNPs
rs10914144 and rs2038479. (C) Further close-up of the region of the MEIS1 peak in
intron 2 showing RNA-seq peak, sequence location of the longest 5RACE clone,
alternative transcript ENST00000523513, and 2 EST clones as well as position of
variant rs2038479.
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gene transcription via the transcription factor MEIS1 or one of
its binding partners.
The first step in exploring this notion was to establish a
comprehensive catalog of genes regulated by MEIS1. For this, we
performed a ChIP-seq experiment in the megakaryocytic cell line
CHRF. This revealed MEIS1 binding events in a set of 1285 genes
(Figure 1A-B), and this gene set showed a number of highly
significant and interesting features. First, the set was strongly
enriched for the terms relevant to megakaryopoiesis and PLT
biology (Table 1). Second, there was an excess of genes, which are
relatively overexpressed in MKs compared with the other 7 mature
blood cell elements (Figure 1B; P  5  1019). Furthermore, 6 of
the 57 MK overexpressed genes (ABCC4, DNM3, LRRC16A,
PDIA5, TPM4, and ZFPM2) harbored a sentinel GWAS SNPs
Figure 4. Identification of functional SNP rs2038479 in a novel, lineage-specific promoter. (A) Relative DNM3 transcript levels in PLTs from persons homozygous for the
major or minor allele of variant rs2038479. Quantitative real-time RT-PCR results with a probe specific for the novel exon 2B-exon 3 boundary (left) versus the annotated exon
2-exon 3 boundary (right) (n  24/23, unpaired t test, including Welch correction for unequal variances). (B) Relative transcript abundance of tissues as measured by
quantitative PCR. MK indicates MK; EB, erythroblast; and CB, cerebellum. n  3. Error bars represent SD, relative to EB  1. (C) Quantitative PCR comparison of 2 major
DNM3 transcripts during MK maturation (n  3). Error bars represent SD, relative to annotated transcript day 0  1. (D) In vitro dual Luciferase reporter assay of promoter
activity of the region 5 of alternative exon 2B, including variant rs2038479 compared with the consensus promoter 5 of exon 1. Left: Megakaryocytic CHRF cells. Right:
Medulloblastoma cells 1603MED, relative to empty firefly vector  100%. Error bars represent SD. The significance of the effect of the variant at the alternative promoter
(P  .002) was determined using a linear mixed model based on 3 independent experiments with 3 replicates per experiment.
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(Figure 1B). Finally, the GW prioritization through co-occurrence
of MEIS1 binding events with association SNPs identified 4 of the
latter 6 genes plus SNP rs342293 at 7q22.3. Thus, not only did GW
profiling of MEIS1 binding sites support the assumption that
MEIS1 has an important role in conferring the PLT its cellular
identity, but it also supported our assumption that allelic alteration
of gene regulation by MEIS1 or its binding partners is possibly
responsible for the observed associations with MPV and PLT at
5 GWAS loci.
We selected the DNM3 gene on chromosome 1 of these
5 GWAS loci for further functional studies. The gene spans 571 kb,
has 21 exons, and is the single gene in the recombination interval
that harbored the PLT-volume sentinel SNP rs10914144. We
therefore reasoned that either the sentinel SNP or one of its proxy
SNPs was highly likely to regulate the transcription of the DNM3
gene itself and not one of the other more distantly removed
cis-positioned genes. Indeed, the analysis of 3 new GW datasets
(Figure 3B-C) confirmed this assumption. It showed that SNP
rs2038479, one of the proxy SNPs of the sentinel SNP,
co-occurs with the MEIS1 binding event in the second intron of
the DNM3 locus. The FAIRE analysis showed that this SNP is at
a position of open chromatin in CHRF cells (Figure 3B), which
is absent in the erythroid K562 cell line (data not shown). The
lineage-restricted open chromatin signature around SNP
rs2038479 together with the presence of a MEIS1 binding event
and already published ChIP-seq datasets from MKs35 is strongly
suggestive of a regulatory element specific for the MK lineage at
this position (see supplemental Figure 8). Indeed, the sequenc-
ing of RNA from MKs showed that the same region is
transcribed (Figure 3B), and suggested that the first 2 exons
were transcribed at much lower levels. The presence of an
alternative transcription start site and DNM3 transcript with
exon 2B as a first exon was confirmed by 5RACE analysis and
by quantitative PCR tests with transcript specific probes (Figure
4B; supplemental Figures 5 and 6). Moreover, we showed that
the levels of the alternative transcript increase sharply during
megakaryopoiesis (Figure 4C).
A recall study of persons from the Cambridge BioResource was
used to compare the levels of the alternative DNM3 transcript in
PLTs between 2 groups of volunteers each, homozygous for the
major (n  24) and minor alleles (n  23) of rs10914144 and
rs2038479, respectively. Both the MPV and RNA levels between
the groups differed significantly (Figures 2C and 4A), indicating
that the minor allele dictates lower levels of the DNM3 transcript
and these reduced levels are possibly causative of the formation of
smaller PLTs. This in vivo observation was corroborated by the
results of Luciferase-reporting assays, which revealed a significant
lower signal in CHRF cells for the reporter construct containing the
minor allele compared with the signal produced by the same
construct harboring the major allele (Figure 4D). If rs2038479 is
indeed the causative variant, this variant would have been expected
to have a lower P value in the GWAS. Closer inspection of the
meta-analysis revealed that rs2038479 (P  2.6  1022 for asso-
ciation with MPV) was genotyped or imputed in a smaller
number of samples than rs10914144, consequently resulting in a
higher P value.
DNM3 is a member of the dynamin family of large GTPases
that each contain an amino-terminal GTPase domain, 3 central
domains (middle, pleckstrin homology, and coiled coil) involved in
self-assembly and membrane binding, and a carboxy-terminal
proline-rich domain that links to SH3 domain-containing signaling/
cytoskeletal partner proteins.36 The dynamins have been shown to
mediate endocytosis of clathrin-coated pits, vesicle budding, and
pseudopodia formation.37-40 The DNM3 protein has been observed
immunochemically in human MK and murine pro-PLTs.30 Interest-
ingly, silencing of the DNM3 gene in human CD34 hematopoietic
precursor cells seems to impair the formation of MKs, although this
is possibly caused by the absence of the consensus DNM3 protein
in precursor cells.41 Here we provide evidence that pharmacologic
inhibition of dynamin GTPase activity inhibits pro-PLT formation
(Figure 5).
In conclusion, we have obtained evidence that 5 of the
68 GWAS SNPs for PLT count and volume are colocalized with a
MEIS1 binding event. By focusing on one of these sites, we
provide strong evidence that variant rs2038479 in the DNM3
locus is the functionally causative allele, which underlies the
observed association with PLT volume, controlling a MK-
specific alternative promoter of the DNM3 gene involved in PLT
formation. Importantly, expression levels and promoter activity
Figure 5. Inhibition of dynamin in MK cultures. (A) Rep-
resentative phase-contrast photomicrographs from the
2 treatments shown. DMSO was used at 0.3% final,
DynaSore at 100M final (taken with a 20 objective).
Bar represents 50 m. (B) The proportion of murine MK
developing pro-PLTs after 4 days culture of fetal liver
cells, quantified as stated in “Methods.”
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of the MK transcript are significantly and concordantly associ-
ated with the genotype of the original GWAS association SNP
(rs10914144) and its proxy variant rs2038479, which resides at
a MEIS1 binding site and marks the position of the alternative
promoter. A scheme showing the 2 SNPs and their relationship
to DNM3 gene transcription and PLT volume is shown in Figure
6. Further studies are required to define the functional role of the
alternative DNM3 transcript in megakaryopoiesis and PLT
formation.
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